Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

mal responses was, as previously reported, 44% (18 out of 41 patients evaluable for response). Of the 18 responding patients (44%), 8 out of 14 patients were bortezomib-nave (57%); 7 out of 16 patients were bortezomib-pretreated patients (44%); and 3 out of 11 patients were bortezomib-refractory (27%). Responses in the bortezomib-refractory patients continue to show prolonged duration (at least 10 months at the time of data presentation at ASCO in June 2007) and meaningful reduction of serum/urinary M-protein (greater than 89%). The combination of tanespimycin and bortezomib was well-tolerated.

Kosan has been granted orphan drug designation for tanespimycin in multiple myeloma in both the US and European Union.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with R
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Reportbuyer.com has added ... Co-development Terms & Agreements in Pharma, Biotech ... The Co-development Terms and Agreements ... comprehensive understanding and unprecedented access to the ... the worlds leading life science companies. ...
(Date:8/27/2014)... and MENLO PARK, Calif. , Aug. ... DMPI), developer of advanced cancer therapeutics , will ... Annual Rodman & Renshaw Global Investment Conference, sponsored by ... take place Tuesday, September 9th at 2:55 p.m. EDT ... New York Palace Hotel in New York ...
(Date:8/27/2014)... , Aug. 27, 2014 Research ... "Global Pulse Oximeter Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The pulse oximeter market analysis is provided ...
Breaking Medicine Technology:Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 3Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 4Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 5Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 6Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 7DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4Global Pulse Oximeter Industry Report 2014 2
... PITTSBURGH, Nov. 10, 2011 Building on the success ... Positive Airway Pressure) mask, Circadiance is proud to introduce ... users will hardly know it,s there. Used ... Feather Weight Tube from Circadiance complements the CPAP mask ...
... VILLAGE, Colo., Nov. 10, 2011 Ampio Pharmaceuticals, ... the "Company"), a company that discovers and develops ... molecular entities ("NMEs"), today announced that an IRB ... for Allergy and Asthma in Denver, Colorado indicates ...
Cached Medicine Technology:Circadiance Launches Revolutionary New CPAP Tube 2Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation 2Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation 3
(Date:8/27/2014)... Delta, a reliable supplier of high quality ... D7R Dozers to its used bulldozer collection. ... that all these items are offered with deep discounts. ... Delta’s market share in the coming September. , ... offer; he has much confidence in the discounted Used ...
(Date:8/27/2014)... Philadelphia, PA. Inc. magazine ranked Holganix as No. ... exclusive ranking of the nation’s fastest-growing privately held companies. ... most important segment of the economy - America’s independent ... members of the Inc. 500 list include Dell, LinkedIn, ... world’s greatest companies have had their start on the ...
(Date:8/27/2014)... Diego, CA (PRWEB) August 27, 2014 ... insurance policies will now be easier for the public ... insurance prices that are promoted in all 50 states ... . , The different insurers that are generating ... made it possible for adults to use the programmed ...
(Date:8/27/2014)... August 27, 2014 Today, Zane Benefits, ... on compliance tips for administering a premium reimbursement plan. ... in full effect, compliance is top of mind for ... to individual health insurance and premium reimbursement, there are ... In the 35 minute webinar, Zane Benefits President, Rick ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Top 10 Best ... compared many Linux hosting suppliers and announced iPage, Bluehost and ... USA, UK, Canada, Australia and Europe to buy useful hosting ... the most reliable suppliers, iPage has been serving ... years’ development, it has grown into a leader in the ...
Breaking Medicine News(10 mins):Health News:Reliable Supplier Delta Adds New Items To Its Used Bulldozer Collection 2Health News:Inc Magazine Unveils 33rd Annual List of America's Fastest-Growing Private Companies - the Inc. 500 2Health News:Home Insurance Prices for All 50 States Now Supplied at Consumer Insurance Portal Online 2Health News:Zane Benefits Announces Upcoming Webinar on Compliance 2Health News:Well-known SEO Hosts Review Site Top10BestSEOHosting.com Recommends iPage, Bluehost and GoDaddy To Webmasters 2
... topical compound is as effective at treating the skin ... the standard therapy, a less-available, costlier compound injected into ... team from Johns Hopkins University , Harvard ... by Reza F. Ghohestani, M.D., Ph.D., director of the ...
... Receives EU and US Approvals for Intravenous Formulation of ... Sachet PresentationKENILWORTH, N.J., March 5 Schering-Plough Corporation (NYSE: ... Commission and the US FDA both approved the intravenous ... already approved oral form of the drug. Temozolomide ...
... to ExpertsBETHESDA, Md., March 5 The American College of ... the March issue of The American Journal of Gastroenterology. ... update of those published by ACG in 2000. Key ... , ...
... acquisition of NMHC drives GAAP earnings per share growth, ... up from $6.5 million in Q4, ... Corp. ("SXC" or the "Company") (NASDAQ: SXCI , TSX: ... ended December 31, 2008. Financial references are in U.S. dollars unless ...
... Anti-Doping Agency (WADA) has banned athletes from using bottled ... of the sports that it governs.LAKE FOREST, Calif., March ... Anti-Doping Agency (WADA), bottled or canned oxygen is banned ... "Artificially enhancing the uptake, transport or delivery of oxygen ...
... imaging and file conversion services available through Lifeboat,s reseller network; ... , ... Northglenn, CO (PRWEB) March ... the imaging industry, today announced a distribution agreement with Lifeboat ...
Cached Medicine News:Health News:The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 3Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 5Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 6Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 7Health News:American College of Gastroenterology Issues Updated Colorectal Cancer Guidelines 2Health News:American College of Gastroenterology Issues Updated Colorectal Cancer Guidelines 3Health News:American College of Gastroenterology Issues Updated Colorectal Cancer Guidelines 4Health News:SXC Health solutions announces strong fourth quarter and year end financial results 2Health News:SXC Health solutions announces strong fourth quarter and year end financial results 3Health News:SXC Health solutions announces strong fourth quarter and year end financial results 4Health News:SXC Health solutions announces strong fourth quarter and year end financial results 5Health News:SXC Health solutions announces strong fourth quarter and year end financial results 6Health News:SXC Health solutions announces strong fourth quarter and year end financial results 7Health News:SXC Health solutions announces strong fourth quarter and year end financial results 8Health News:SXC Health solutions announces strong fourth quarter and year end financial results 9Health News:SXC Health solutions announces strong fourth quarter and year end financial results 10Health News:SXC Health solutions announces strong fourth quarter and year end financial results 11Health News:SXC Health solutions announces strong fourth quarter and year end financial results 12Health News:SXC Health solutions announces strong fourth quarter and year end financial results 13Health News:SXC Health solutions announces strong fourth quarter and year end financial results 14Health News:SXC Health solutions announces strong fourth quarter and year end financial results 15Health News:SXC Health solutions announces strong fourth quarter and year end financial results 16Health News:SXC Health solutions announces strong fourth quarter and year end financial results 17Health News:SXC Health solutions announces strong fourth quarter and year end financial results 18Health News:SXC Health solutions announces strong fourth quarter and year end financial results 19Health News:SXC Health solutions announces strong fourth quarter and year end financial results 20Health News:Oxygen4Energy: International Sports News - World Anti-Doping Agency (WADA) Bans Oxygen Use 2Health News:Lifeboat Distribution and ImageDoc USA Sign Distribution Agreement 2
Microplate incubator shaker used in a variety of immunoassay and research procedures requiring microplates....
... especially suited for cell analysis and ... allows to analyze scatter signals in ... channels. Data acquisition, analysis, and real-time ... PC employing Partec DPAC software, built-in ...
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
... The IMMULITE 1000 immunoassay system ... use, reliability, robust hardware and excellent ... onboard reagents and accommodates onboard dilutions, ... , , Worldwide, IMMULITE 1000 (and ...
Medicine Products: